

Atsushi Naganuma

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7498172/publications.pdf>

Version: 2024-02-01

19
papers

260
citations

933447

10
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

321
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan. <i>Cancer Medicine</i> , 2023, 12, 345-357.	2.8	5
2	Efficacy of Zinc Acetate Treatment for Patients with Decompensated Liver Cirrhosis Complicated by Hypozincemia. <i>Biological Trace Element Research</i> , 2022, 200, 497-504.	3.5	6
3	Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. <i>Oncology</i> , 2022, 100, 65-73.	1.9	3
4	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. <i>Hepatology Research</i> , 2022, 52, 462-470.	3.4	18
5	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. <i>Cancer Medicine</i> , 2022, 11, 3796-3808.	2.8	21
6	Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. <i>Oncology</i> , 2022, 100, 449-459.	1.9	3
7	Prediction of oral intake recovery for inpatients with aspiration pneumonia by videoendoscopic evaluation using the Hyodo-Komagane score in Japan. <i>Journal of Oral Rehabilitation</i> , 2021, 48, 55-60.	3.0	4
8	The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study. <i>Oncology</i> , 2021, 99, 203-214.	1.9	18
9	Lenvatinib for Hepatocellular Carcinoma: A Literature Review. <i>Pharmaceuticals</i> , 2021, 14, 36.	3.8	30
10	Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study. <i>Oncology</i> , 2021, 99, 641-651.	1.9	9
11	Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the <scp>FibroScan</scp> aspartate aminotransferase score. <i>JGH Open</i> , 2021, 5, 1183-1189.	1.6	21
12	Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. <i>Hepatology Research</i> , 2020, 50, 382-395.	3.4	28
13	Usefulness of Percutaneous Transesophageal Gastro-Tubing in Patients Receiving Chemoradiotherapy for Advanced Esophageal Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2020, 12, 901-908.	0.7	1
14	Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. <i>Cancers</i> , 2020, 12, 2906.	3.7	17
15	Role of deleterious single nucleotide variants in the coding regions of TNFAIP3 for Japanese autoimmune hepatitis with cirrhosis. <i>Scientific Reports</i> , 2019, 9, 7925.	3.3	10
16	Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin. <i>Hepatology Research</i> , 2018, 48, E347-E353.	3.4	10
17	Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. <i>Hepatology Research</i> , 2018, 48, 411-423.	3.4	36
18	Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015. <i>Hepatology Research</i> , 2017, 47, 435-445.	3.4	16

#	ARTICLE	IF	CITATIONS
19	Calf circumference and stroke are independent predictors for an improvement in the food intake level scale in the Japanese sarcopenic dysphagia database. European Geriatric Medicine, 0, , .	2.8	4